Phase 2 Schizophrenia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing and able to give informed consent for all parts of the study
- People who have been diagnosed with schizophrenia according to standard diagnostic guidelines (DSM-5), confirmed through a structured clinical interview
- People whose doctor (the investigator) believes would benefit from long-term medication treatment for schizophrenia
- People whose doctor (the investigator) considers suitable for outpatient care and who live in a stable housing situation
- People who have at least one trusted person (such as a family member, carer, or long-term clinic staff member) who is available to take part in certain assessments
Who may not be able to join:
- People who have another mental health condition (besides schizophrenia) that has been the main cause of their symptoms or difficulties in daily life within the past 12 months
- People who would be stopping a current antipsychotic medication that is working well and being tolerated, specifically in order to enter this trial
- People who have received certain treatments that are not permitted during the screening period (unless those treatments are stopped before the study officially begins)
- People who have a significant or unstable physical health condition identified at the time of screening or at the start of the study
- People who have notable abnormal results from a physical examination, heart tracing (ECG), or blood/lab tests at screening or at the start of the study
- People who are considered to be at elevated risk of suicidal behaviour
- People who have a known allergy to the study drug (ML-007C-MA), its active ingredients, or any of its components
- People who have been diagnosed with a moderate to severe substance use disorder in the past 12 months (not including tobacco or caffeine), as confirmed by a clinical interview
- People whose history and the investigator's assessment suggest an elevated risk of violent or destructive behaviour
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: MapLight Therapeutics, MapLight Therapeutics
Phone: +1 650 839 4385
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To assess the safety and tolerability of long-term ML-007C-MA administration in adult participants with schizophrenia
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.